DRUG TPI-287-18: Phase 2 Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent or Progressive Glioblastoma Following a Bevacizumab Alone

Project: Research project

Project Details

StatusFinished
Effective start/end date8/19/14 → 8/19/17

Funding

  • Cortice Biosciences, Inc. (TPI-287-18)